Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, May 30, 2023 -- Revive Therapeutics Ltd. , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced... | May 30, 2023

Related Keywords

Toronto ,Ontario ,Canada ,Michael Frank ,Therapeutics Ltd ,Psilocin Pharma Corp ,Company Us Food Drug Administration ,Drug Administration ,Data Safety Monitoring Board ,Institutional Review Board ,Orphan Drug ,Fast Track ,Breakthrough Therapy ,Rare Pediatric Disease ,Revive Therapeutics Ltd Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Evive ,Herapeutics ,Specialty ,Life ,Ciences ,Company ,Ocused ,N ,The ,Research ,End ,Development ,F ,Or ,Medical ,Needs ,Are Rvv Ca7615161030 ,